Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.

Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM. · 2018

Read Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. by Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5805863.txt.

Introduction

Copson and co-authors follow young breast cancer patients with BRCA faults. Faults in BRCA1 or BRCA2 raise cancer risk. Whether they worsen survival was unclear from past studies. The POSH study tests this question in women diagnosed at age 40 or younger.

The study recruited 2,733 women from 127 British hospitals. Testing found a BRCA fault in 338 patients, or 12 percent. After a median 8.2 years, survival matched non-carriers at 2, 5, and 10 years. Triple-negative carriers fared better at 2 years only. Readers get firm and welcome news: a BRCA fault alone does not doom young patients.

Catalog record

CREATORCopson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5805863

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study By Ellen R Copson, Tom C Maishman, Will J Tapper, Ramsey I Cutress, Stephanie Greville-Heygate, Douglas G Altman, Bryony Eccles, Sue Gerty, Lorraine T Durcan, Louise Jones, D Gareth Evans, Alastair M Thompson Published in: The Lancet. Oncology DOI: 10.1016/S1470-2045(17)30891-4 ABSTRACT Summary Background Retrospective studies provide conflicting interpretations of the effect of inherited genetic factors on the prognosis of patients with breast cancer. The primary aim of this study was to determine the effect of a germline BRCA1 or BRCA2 mutation on breast cancer outcomes in patients with young-onset breast cancer. Methods We did a prospective cohort study of female patients recruited from 127 hospitals in the UK aged 40 years or younger at first diagnosis (by histological confirmation) of invasive breast cancer. Patients with a previous invasive malignancy (except non-melanomatous skin cancer) were excluded. Patients were identified within 12 months of initial diagnosis. BRCA1 and BRCA2 mutations were identified using blood DNA collected at recruitment. Clinicopathological data, and data regarding treatment and long-term outcomes, including date and site of disease recurrence, were collected from routine medical records at 6 months, 12 months, and then annually until death or loss to follow-up. The primary outcome was overall survival for all BRCA1 or BRCA2 mutation carriers (BRCA-positive) versus all non-carriers (BRCA-negative) at 2 years, 5 years, and 10 years after diagnosis. A prespecified subgroup analysis of overall survival was done in patients with triple-negative breast cancer. Recruitment was completed in 2008, and long-term follow-up is continuing. Findings Between Jan 24, 2000, and Jan 24, 2008, we recruited 2733 women. Genotyping detected a pathogenic BRCA mutation in 338 (12%) patients (201 with BRCA1, 137 with BRCA2). After a median follow-up of 8·2 years (IQR 6·0–9·9), 651 (96%) of 678 deaths were due to breast cancer. There was no significant difference in overall survival between BRCA-positive and BRCA-negative patients in multivariable analyses at any timepoint (at 2 years: 97·0% [95% CI 94·5–98·4] vs 96·6% [95·8–97·3]; at 5 years: 83·8% [79·3–87·5] vs 85·0% [83·5–86·4]; at 10 years: 73·4% [67·4–78·5] vs 70·1% [67·7–72·3]; hazard ratio [HR] 0·96 [95% CI 0·76–1·22]; p=0·76). Of 558 patients with triple-negative breast cancer, BRCA mutation carriers had better overall survival than non-carriers at 2 years (95% [95% CI 89–97] vs 91% [88–94]; HR 0·59 [95% CI 0·35–0·99]; p=0·047) but not 5 years (81% [73–87] vs 74% [70–78]; HR 1·13 [0·70–1·84]; p=0·62) or 10 years (72% [62–80] vs 69% [63–74]; HR 2·12 [0·82–5·49]; p= 0·12). Interpretation Patients with young-onset breast cancer who carry a BRCA mutation have similar survival as non-carriers. However, BRCA mutation carriers with triple-negative breast cancer might have a survival advantage during the first few years after diagnosis compared with non-carriers. Decisions about timing of additional surgery aimed at reducing future second primary-cancer risks should take into account patient prognosis associated with the first malignancy and patient preferences. Funding Cancer Research UK, the UK National Cancer Research Network, the Wessex Cancer Trust, Breast Cancer Now, and the PPP Healthcare Medical Trust Grant. INTRODUCTION Although only 5% of breast cancers are diagnosed in women aged younger than 40 years, a high proportion of deaths from breast cancer occur in this age group, which includes a higher number of patients who carry a pathogenic BRCA1 or BRCA2 mutation compared with patients with onset of breast cancer at an older age.1, 2, 3 Second primary breast cancers are more frequent in high-risk gene carriers, and this higher frequency drives early genetic testing to inform surgical decision making; however, whether a germline BRCA1 or BRCA2 mutation has independent prognostic implications after an initial cancer diagnosis is unclear. BRCA1 loss of function mutations are associated with high-histological-grade, oestrogen-receptor-negative, progesterone-receptor-negative, and HER2-negative (triple negative) breast cancer with a basal-like gene expression profile.4 BRCA2-associated breast tumours are usually high-grade, oestrogen-receptor positive, and HER2-negative.5, 6 BRCA1 mutation carriers have been reported to have enhanced sensitivity to neoadjuvant chemotherapy with cytotoxic drugs.7 Research in contextEvidence before this studyAt the initiation of this cohort study (Dec 3, 1999), we searched the PubMed database using the search terms [BRCA1 OR BRCA2] AND [breast cancer or breast neoplasm] AND [survival OR prognosis OR mortality] and identified a few published retrospective studies reporting prognosis in BRCA mutation carriers. On Dec 5, 2016, we did another PubMed search for studies of patients who carried a BRCA1 or BRCA2 mutation and their prognosis, using the following search terms: “(BRCA) AND (survival or prognosis or outcome or mortality) AND (breast neoplasms or breast neoplasm or breast cancer or breast tumour)”. Our search was not limited by date or language. We also hand-searched references cited in review papers for additional papers. Previous studies and meta-analyses have reported inconsistent effects of BRCA1 and BRCA2 mutations on the outcomes of early breast cancer with better, worse, and similar outcomes for patients with a BRCA1 or BRCA2 mutation compared with patients with sporadic breast cancer. These conflicting results might be explained by methodological issues with ascertainment biases introduced by retrospective and selective identification of cases, incomplete genetic testing, small numbers, an absence of adjustment for clinical variables, including treatment, and short follow-up.Added value of this studyPOSH is, to our knowledge, the largest prospective cohort study to compare breast cancer outcomes of patients with a BRCA1 or BRCA2 mutation with patients with sporadic cancer. Our findings showed that patients with young-onset breast cancer who have a BRCA mutation have a similar overall survival to non-carriers. However, in patients with triple-negative breast cancer, BRCA mutation carriers might have a survival advantage compared with non-carriers during the first few years after diagnosis. Our study was strengthened by unbiased recruitment, universal and central genetic testing at the end of the study, and comprehensive pathological, clinical, and follow-up data.Implications of all the available evidenceDecisions about timing of risk-reducing surgery should take into account primary tumour prognosis and patient preference. Published studies and meta-analyses have reported better, worse, and similar outcomes for patients with a BRCA1 or BRCA2 mutation compared with patients with sporadic breast cancer.8, 9, 10, 11, 12, 13, 14 A comprehensive meta-analysis of 66 studies of breast cancer survival in patients with a BRCA1 or BRCA2 mutation compared with non-carrier patients or the general breast cancer population, which assessed study quality as well as outcome data, concluded that “it is not yet possible to draw evidence based conclusions about the association between BRCA1 [or] BRCA2 mutation carriership and breast cancer prognosis”.12 We undertook the Prospective Outcomes in Sporadic versus Hereditary breast cancer (POSH) study, the primary aim of which was to determine the effect of inherited BRCA1 or BRCA2 mutations on outcomes in patients with young-onset breast cancer.15, 16 METHODS Study design and participants We did a prospective cohort study at 127 hospitals in the UK (appendix pp 1–2). We recruited young women (aged 18–40 years) diagnosed with primary breast cancer in the UK. Patients were eligible if they were diagnosed with invasive breast cancer aged 40 years or younger. Potential recruits were identified by local breast cancer clinicians, nurses, or research clinical trial practitioners within 12 months of initial diagnosis of invasive breast cancer and the date of diagnosis was defined as the first histological confirmation

Read the complete text